10 Health Care Stocks With Whale Alerts In Today's Session
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth.
HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating
Alnylam Pharmaceuticals (ALNY) has an average outperform rating and a price target range of $138 to $400, according to analysts polled by Capital IQ.
Alnylam Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Alnylam Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $400
HC Wainwright & Co. analyst Patrick Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $395 to $400.
Alnylam Issues 2023 Corporate Responsibility Report
Alnylam Issues 2023 Corporate Responsibility ReportMay 07, 2024– Highlighted New Disclosures of Company's Impact on the Environment—Including Multiyear Data on Greenhouse Gas (GHG) Emissions, Energy,
The Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
Alnylam Pharma (ALNY) Receives a Hold From Oppenheimer
Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $225 Price Target
Chardan Capital analyst Keay Nakae maintains Alnylam Pharmaceuticals with a Buy and maintains $225 price target.
RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight
Strong Financial Growth and Promising Clinical Trials Bolster Buy Rating for Alnylam Pharmaceuticals
Research Alert: CFRA Keeps Buy View On Shares Of Alnylam Pharmaceuticals, Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We cut our target to $165 from $188 on o
Earnings Call Summary | Alnylam Pharmaceuticals(ALNY.US) Q1 2024 Earnings Conference
The following is a summary of the Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript:Financial Performance:Alnylam Pharmaceuticals reported Q1 2024 product revenue of $365 million,
Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $200 Price Target
Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals with a Buy and maintains $200 price target.
Needham: Reiterates Alnylam Pharmaceuticals (ALNY.US) rating and adjusted from buy to buy rating, target price is $200.00.
Needham: Reiterates Alnylam Pharmaceuticals (ALNY.US) rating and adjusted from buy to buy rating, target price is $200.00.
Alnylam Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 32.63% Needham → $200 Reiterates Buy → Buy 03/27/2024 55.17% BMO Capital $234 → $234 Maintains
No Data